Cancer Targeted Technology

Cancer Targeted Technology (CTT) develops innovative cancer-targeting drugs that can accurately detect, stratify, and treat early- and late-stage diseases while monitoring treatment effectiveness to improve patient survival and quality of life.CTT is a biotechnology company commercializing innovative small molecules that target key enzyme targets in cancer. CTT’s rationally designed and patented targeting scaffolds recognize molecular targets, such as prostate-specific membrane antigen (PSMA), with unparalleled binding properties, setting them apart from competitors. PSMA is a specific biomarker expressed in nearly 90% of prostate tumors. Increased PSMA expression correlates with disease progression, while its normal tissue expression ranges from negative to low. CTT's small molecule drugs are unique because they irreversibly bind to the PSMA target and are rapidly internalized by PSMA-expressing tumor cells. As a result, more of the drug reaches and remains at the tumor site.